Trovafloxacin is active against Toxoplasma gondii

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 8, 1996, Pages 1855-1859

  Khan, Anis A ^a   Slifer, Teri ^a   Araujo, Fausto G ^a   Remington, Jack S ^a,b  

^a PALO ALTO MEDICAL FOUNDATION   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; FLEROXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEMAFLOXACIN; TOSUFLOXACIN; TROVAFLOXACIN;

ANIMAL CELL; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; INFECTION PREVENTION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TOXOPLASMA GONDII; TOXOPLASMOSIS;

EID: 0029821424     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.8.1855     Document Type: Article

References (38)

1. Aldridge, K. E., and D. Ashcraft. 1995. Comparison of the in vitro activity of CP 99,219 to that of ciprofloxacin and other antimicrobials against clinical strains of the Bacteroides fragilis group, p. 153, abstr. F232. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
2. Araujo, F. G., J. Huskinson, and J. S. Remington. 1991. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob. Agents Chemother. 35:293-299.
3. Araujo, F. G., J. Huskinson-Mark, W. E. Gutteridge, and J. S. Remington. 1992. In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii. Antimicrob. Agents Chemother. 36:326-330.
4. Araujo, F. G., and J. S. Remington. 1974. Effect of clindamycin on acute and chronic toxoplasmosis in mice. Antimicrob. Agents Chemother. 5:647-651.
5. Arguedas-Mohs, A., C. Loaiza, R. Riviera, S. L. Vargas, E. M. S. Goodall, J. S. Bradley, J. Vincent, R. Teng, and J. N. Walterspiel. 1995. CSF penetration of IV trovafloxacin in children. In Program and abstracts of the 1st International Pediatric Infectious Disease Conference. Pediatric Infectious Diseases Society of America and European Society Pediatric Infectious Diseases, Monterey, Calif.
6. Brighty, K. E., T. D. Gootz, A. Girard, R. Shanker, M. J. Castaldi, D. Girard, S. A. Miller, and J. Faiella. 1995. Prodrugs of CP-99,219 for intravenous administration; synthesis and evaluation resulting in identification of CP-116,517. In Program and abstracts of the 7th European Congress of Clinical Microbiology and Infectious Disease, Vienna, Austria.
7. Carbone, L. G., B. Bendixen, and G. B. Appel. 1988. Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome. Am. J. Kidney Dis. 12:72-75.
8. Cohn, J., A. McMeeking, W. Cohen, J. Jacons, and R. S. Holzman. 1989. Evaluation of the policy of empiric treatment of suspected Taxoplasma encephalitis in patients with the acquired immunodeficiency syndrome. Am. J. Med. 86:521-527.
9. Cook, M. K., and L. Jacobs. 1958. In vitro investigation on the action of pyrimethamine against Toxoplasma gondii. J. Parasitol. 44:280-288.
10. Dannemann, B. R., V. A. Morris, F. G. Araujo, and J. S. Remington. 1989. Assessment of human natural killer and lymphokine-activated killer cell cytotoxicity against Toxoplasma gondii trophozoites and cysts. J. Immunol. 143:2684-2691.
11. Derouin, F., C. Sarfati, B. Beauvais, Y. J. F. Garin, and M. Lariviere. 1990. Prevalence of pulmonary toxoplasmosis in HIV-infeeted patients. J. Acquired Immune Defic. Syndr. 4:1036.
12. Espinoza, A. M., N.-X. Chin, A. Novelli, and H. C. Neu. 1988. Comparative in vitro activity of a new fluorinated 4-quinolone, T-3262 (A-60969). Antimicrob. Agents Chemother. 32:663-670.
13. Eyles, D. E., and M. Coleman. 1953. Synergistic effect of sulfadiazine and Daraprim against experimental toxoplasmosis in the mouse. Antibiot. Chemother. 3:483-490.
14. Eyles, D. E., and N. Coleman. 1955. An evaluation of the curative effects of pyrimethamine and sulfadiazine, alone and in combination, on experimental toxoplasmosis. Antibiot. Chemother. 5:529-539.
15. Fujimaki, K., T. Noumi, I. Saikawa, M. Inoue, and S. Mitsuhashi. 1988. In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone. Antimicrob. Agents Chemother. 32:827-833.
16. Goodings, B. B., and R. N. Jones. 1993. In vitro antimicrobial activity of CP-99,219, a novel azahicyclo-naphthyridone. Antimicrob. Agents Chemother. 37:349-353.
17. Hooper, D. C., and J. S. Wolfson. 1991. Fluoroquinolone antimicrobial agents. N. Engl. J. Med. 324:384-394.
18. Israelski, D. M., and J. S. Remington. 1988. Toxoplasmic encephalitis in patients with AIDS. Infect. Dis. Clin. N. Am. 2:429-445.
19. Kenny, G. E., and F. D. Cartwright. 1995. Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone: CP-99,219-27, p. 154. abstr. F236. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
20. Kocagöz, S., D. Gür, S. Ünal, and H. E. Akalin. 1995. In vitro activity of CP-99,219 against clinical isolates, p. 153, abstr. F231. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
21. Mann, H. J., P. B. Bitterman, A. C. Anderson, R. Teng, A. Johnson, M. Avery, and J. Vincent. 1995. CP-99,219 penetration into human bronchial tissues and fluids following the administration of a single dose, p. 155, abstr. F241. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
22. Martin, D. H., R. B. Jones, and R. B. Johnson. 1995. A phase II study of CP-99,219-27 (CP) for the treatment of Chlamydia trachomatis (Ct) infections, p. 332, abstr. LM33. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
23. Maxwell, A. 1992. The molecular basis of quinolone action. J. Antimicrob. Chemother. 30:409-416.
24. Mitsuyama, J.-I., Y. Itoh, M. Takahat, S. Okamoto, and T. Yasuda. 1992. In vitro antibacterial activities of tosufloxacin against and uptake of tosufloxacin by outer membrane mutants of Escherichia coli, Proteus mirabilis, and Salmonella typhimurium. Antimicrob. Agents Chemother. 36:2030-2036.
25. Noumi, T., N. Nishida, S. Minami, Y. Watanabe, and T. Yashuda. 1990. Intracellular activity of tosufloxacin (T-3262) against Salmonella enteritidis and ability to penetrate into tissue culture cells of human origin. Antimicrob. Agents Chemother. 34:949-953.
26. Oksenhendler, E., J. Cadranel, C. Sarfati, C. Katlama, A. Datry, C. Marche, M. Wolf, P. Roux, F, Derouin, and J. P. Clauvel. 1990. Toxoplasma gondii pneumonia in patients with the acquired immunodeficiency syndrome. Am. J. Med. 88:18N-21N.
27. Pomeroy, C., and G. A. Filice. 1992. Pulmonary toxoplasmosis: a review. Clin. Infect. Dis. 14:863-870.
28. Sahai, J., T. Heimberger, K. Collins, L. Kaplowitz, and R. Polk. 1988. Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder. Am. J. Med. 84:791-792. (Letter.)
29. Sutclife, J. A., T. D. Gootz, and J. F. Barrett. 1989. Biochemical characteristics and physiological significance of major DNA topoisomerases. Antimicrob. Agents Chemother. 33:2027-2033.
30. Teng, R., L. C. Dogolo, S. A. Willavize, and J. Vincent. 1995. Effect of age and gender on the pharmacokinetics of CP-99,219, a new quinolone antibiotic, in healthy volunteers, p. 154, abstr. F238. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
31. Teng, R., S. C. Harris, D. E. Nix, J. J. Schentag, G. Foulds, and T. E. Liston. 1995. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J. Antimicrob. Chemother. 36:385-394.
32. Torroba, A. L., D. J. Hermida, B. C. Ezpeleta, and Z. E. Munoz. 1988. Metahemoglobinemia secundaria al tratamiento de infecciones oportunistas en pacientes con SIDA. Rev. Clin. Esp. 182:289-290. (Letter.)
33. Van Der Pol, B., and R. B. Jones. 1995. In vitro activity of CP99,219 against Chlamydia trachomatis, p. 154, abstr. F237. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
34. Visalli, M., M. Jacobs, and P. Appelbaum. 1995. Antipneumococcal activity of CP 99,219, ciprofloxacin, lomefloxacin, clinafloxacin, sparfloxacin and cefuroxime by time-kill testing, p. 154, abstr. F233. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
35. Wise, R., D. Mortiboy, J. Child, and J. M. Andrews. 1996. Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219). Antimicrob. Agents Chemother. 40:47-49.
36. Wong, S.-Y., D. M. Israelski, and J. S. Remington. 1994. AIDS associated toxoplasmosis, p. 460-493. In M. A. Sande and P. Volberding (ed.), The medical management of AIDS, 4th ed. The W. B. Saunders Co., Philadelphia.
37. Wong, S.-Y., and J. S. Remington. 1994. Toxoplasmosis in the setting of AIDS, p. 223-257. In S. Broder, T. C. Merigan, and D. Bolognesi (ed.), Textbook of AIDS medicine. The Williams & Wilkins Co., Baltimore.
38. Zimmer, C., K. Storl, and J. Storl. 1990. Microbial DNA topoisomerases and their inhibition by antibiotics. J. Basic Microbiol. 30:209-224.